Celldex Therapeutics Inc. (CLDX)
Celldex Therapeutics Statistics
Share Statistics
Celldex Therapeutics has 66.38M shares outstanding. The number of shares has increased by 0.72% in one year.
| Shares Outstanding | 66.38M |
| Shares Change (YoY) | 0.72% |
| Shares Change (QoQ) | 0.06% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | 64.7M |
| Failed to Deliver (FTD) Shares | 10.02K |
| FTD / Avg. Volume | 1.07% |
Short Selling Information
The latest short interest is 8.3M, so 12.51% of the outstanding shares have been sold short.
| Short Interest | 8.3M |
| Short % of Shares Out | 12.51% |
| Short % of Float | 14.47% |
| Short Ratio (days to cover) | 11.1 |
Valuation Ratios
The PE ratio is -10.31 and the forward PE ratio is -4.82. Celldex Therapeutics's PEG ratio is 0.64.
| PE Ratio | -10.31 |
| Forward PE | -4.82 |
| PS Ratio | 231.8 |
| Forward PS | 1.7 |
| PB Ratio | 2.18 |
| P/FCF Ratio | -10.31 |
| PEG Ratio | 0.64 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Celldex Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 18.91, with a Debt / Equity ratio of 0.01.
| Current Ratio | 18.91 |
| Quick Ratio | 18.91 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | -0.02 |
| Debt / FCF | -0.02 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $37.74K |
| Profits Per Employee | $-848.73K |
| Employee Count | 186 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -48.87% in the last 52 weeks. The beta is 1.59, so Celldex Therapeutics's price volatility has been higher than the market average.
| Beta | 1.59 |
| 52-Week Price Change | -48.87% |
| 50-Day Moving Average | 19.72 |
| 200-Day Moving Average | 28.32 |
| Relative Strength Index (RSI) | 55.41 |
| Average Volume (20 Days) | 935.9K |
Income Statement
In the last 12 months, Celldex Therapeutics had revenue of 7.02M and earned -157.86M in profits. Earnings per share was -2.45.
| Revenue | 7.02M |
| Gross Profit | 7.02M |
| Operating Income | -195.08M |
| Net Income | -157.86M |
| EBITDA | -191.9M |
| EBIT | -195.08M |
| Earnings Per Share (EPS) | -2.45 |
Balance Sheet
The company has 28.36M in cash and 3.81M in debt, giving a net cash position of 24.54M.
| Cash & Cash Equivalents | 28.36M |
| Total Debt | 3.81M |
| Net Cash | 24.54M |
| Retained Earnings | -1.56B |
| Total Assets | 792.34M |
| Working Capital | 707.66M |
Cash Flow
In the last 12 months, operating cash flow was -157.78M and capital expenditures 0, giving a free cash flow of -157.78M.
| Operating Cash Flow | -157.78M |
| Capital Expenditures | 0 |
| Free Cash Flow | -157.78M |
| FCF Per Share | -2.45 |
Margins
Gross margin is 100%, with operating and profit margins of -2778.89% and -2248.76%.
| Gross Margin | 100% |
| Operating Margin | -2778.89% |
| Pretax Margin | -2248.76% |
| Profit Margin | -2248.76% |
| EBITDA Margin | -2733.63% |
| EBIT Margin | -2778.89% |
| FCF Margin | -2247.55% |
Dividends & Yields
CLDX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for CLDX is $46, which is 138.2% higher than the current price. The consensus rating is "Buy".
| Price Target | $46 |
| Price Target Difference | 138.2% |
| Analyst Consensus | Buy |
| Analyst Count | 8 |
Stock Splits
The last stock split was on Feb 11, 2019. It was a backward split with a ratio of 1:15.
| Last Split Date | Feb 11, 2019 |
| Split Type | backward |
| Split Ratio | 1:15 |
Scores
| Altman Z-Score | 13.6 |
| Piotroski F-Score | 3 |